Fosun International (HKG:0656) said unit Shanghai Henlius Biotech's (HKG:2696) board approved the adoption of share option and restricted share unit (RSU) schemes, subject to shareholder approval,
Shares of conglomerate Fosun International closed 1% lower on Monday, while Henlius Biotech closed 5% higher.
Henlius Biotech is planning to make initial grants of 6,985,000 options and 6,985,000 RSUs to 279 participants under the schemes, which will be valid for 10 years.
The potential grantees of the scheme include employees, related entities, and service providers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.